Clinical Trial: 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Brief Summary: The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.
Detailed Summary:
PRIMARY OBJECTIVES:
I. Evaluate 18F FPPRGD2 PET/CT or PET/MRI for prediction and early assessment of response to anti-angiogenesis therapy in patients with non-small cell lung cancer (NSCLC), breast cancer, glioblastoma multiforme (GBM) and other cancers.
OUTLINE:
Patients undergo 18F FPPRGD2 PET/CT or PET/MRI at baseline, 1 week, and 6 weeks (or standard of care follow-up) and 18F FDG PET/CT at baseline and 6 weeks (or standard of care follow-up) .
After completion of study imaging, patients are followed up at 12 months.
Sponsor: Sanjiv Sam Gambhir
Current Primary Outcome: Change in maximum standard uptake values (SUVmax) on 18F FPPRGD2 and 18F FDG PET [ Time Frame: From baseline up to 6 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Progression-free survival [ Time Frame: Up to 1 year ]
Original Secondary Outcome: Same as current
Information By: Stanford University
Dates:
Date Received: March 5, 2013
Date Started: March 2013
Date Completion: March 2019
Last Updated: March 12, 2017
Last Verified: March 2017